Latest News & Features
Americas
The 47th US president will need to address the thorny issues of non-competes, patent rights and drug pricing. 5 November 2024
Americas
A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages. 5 November 2024
Americas
New hire specialises in guiding life sciences and health tech clients through compliance issues | Work includes US regulations, including those enforced by the FDA, Drug Enforcement Administration and the Office of Inspector General. 31 October 2024
Europe
European Commission says fine “proportionate and necessary” after Teva spread misleading information about rival’s product | Teva says it is “deeply disappointed” and will appeal. 31 October 2024
Europe
The government’s autumn budget sends a positive signal but a more comprehensive approach is required to unlock the UK’s potential, says Graeme Moore of Mewburn Ellis. 31 October 2024
Americas
UK High Court judge unconvinced by Pfizer that uniQure’s patent is invalid | Companies in dispute over patents covering haemophilia B therapies in the US, Canada and UK 29 October 2024
Europe
Former head of life sciences at Gowling, joins Cooley’s London office as a partner | Brings expertise in cross-border licensing and collaboration deals in the pharmaceutical, biotech, and medical device sectors. 29 October 2024
Americas
A federal jury finds Masimo’s smartwatches infringe Apple’s blood oxygen patents | Decision results in an award of just $250 for the tech giant | Despite the victory, Masimo says the ruling does not apply to its current products. 29 October 2024
Americas
Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation 24 October 2024
Americas
Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America. 24 October 2024